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ABSTRACT
Cord blood (CB) mononuclear cells (MNCs) can be transplanted in HLA mismatched recipients with limited
graft rejection or graft-versus-host disease (GVHD). Previous studies have shown that naı¨ve T cells and hypo-
responsive dendritic cells are largely represented in CB. Data presented here demonstrate that CB MNCs are
unable to stimulate allogeneic T cell proliferative or cytotoxic responses in standard in vitro assays. However,
a suppressive effect of CB MNCs was ruled out because purified CD341 cells or CD141monocytes stimulated
T cell responses that were not inhibited by add-back of CB MNCs. The lack of antigen-presenting cell (APC)
activity of CB MNCs in primary mixed lymphocyte culture (MLC) did not induce allogeneic T cell anergy. In
fact, rechallenge of T cells with CB CD341 cells, or immature monocyte-derived dendritic cells (iMo-DCs) in
secondaryMLC induced potentT cell proliferative responses. A delayed APC activity of CBMNCswas observed
after stimulation with irradiated allogeneic T cells for 6 days, likely because of the upregulation of CD86 and
HLA-DR on CB cells. Cytotoxic lymphocytes (CTL) were generated after stimulation of blood T cells with
CB MNCs for 4 weeks or CB-derived iMo-DCs for 1 week. Concomitant stimulation of T cells with CB
iMo-DC obtained from 2 CB units resulted in the generation of CTLs specific for each CB, independently of
the CB:CB cell ratio. These data suggest that the APC activity of CB cells possibly increases posttransplant,
and may contribute to delayed graft rejection and/or acute and chronic GVHD.
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Cord blood (CB) is a source of hematopoietic stem
cells (HSCs) increasingly utilized in allogeneic HSC
transplantation of patients with hematologic malig-
nancies who do not have an HLA matched related or
unrelated donor [1,2]. Because the number of nucle-
ated cells available for HSC transplantation is smaller
in CB than in marrow or mobilized peripheral blood,
smaller recipients, such as pediatric patients, usually
represent more suitable candidates for CB transplant.
Besides a quantitative difference of number of cells,
CB differs from other HSC sources also for the preva-
lence of naı¨ve T cells and an overall immunologic im-
maturity and Th2 cytokine skewing of the T cells
included in the graft [2-7]. In addition, studies per-
formed on isolated monocytes, or in vitro-generated872monocyte-derived dendritic cells, have also shown
that CB antigen-presenting cells (APCs) are less
susceptible to complete maturation and activation
compared to their counterparts in adult peripheral
blood [8,9]. These immunologic characteristics may
explain why 1 to 2 HLA antigen-mismatched CB units
can be transplanted with acceptable rates of severe
acute graft-versus-host disease (aGVHD) or rejection.
It is interesting, however, that the immune reconstitu-
tion observed after CB or bone marrow transplanta-
tion seems to be comparable [10,11].
Transplantation of 1 CB unit in adult patients of-
ten results in a more prolonged time to neutrophil
and platelet engraftment compared to bone marrow
or peripheral blood stem cell (PBSC) transplant
because of the limited cell dose infused [12]. Recently,
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tation of 2 CB grafts is an effective method to increase
the total cell dose transplanted in adult patients, and
can shorten the time to hematopoietic engraftment
without increasing the risk of GVHD or rejection
significantly [13]. In addition, in approximately 1/3
of the patients receiving a double CB transplant the
engraftment of cells derived by both CB units was
demonstrated by chimerism analysis on day 21 post-
transplant. However, following this initial phase of
mixed chimerism, only the cells derived from 1 of the
2 CB will permanently engraft the patient, whereas
cells derived from the other CB graft progressively
disappear by means of mechanisms that are yet to be
clarified.
Although the lower incidence of severe aGVHD in
CB transplants compared to bone marrow/peripheral
blood transplants may depend on the inefficient
response of CB T cells, the development of chronic
GVHD (cGVHD) may depend also on the antigen-
presenting function of donor CB cells [14].
In this study, we analyzed the alloantigen-present-
ing function of cells present in CB grafts. Our results
suggest that although CB cells have poor capacity of
stimulating T cell alloresponses, they do not induce
T cell anergy, but rather develop a delayed, but
effective immunogenic activity.
MATERIALS AND METHODS
Cell Separation
The CB is obtained from discarded placentas from
the New York Blood Bank. An institutional review board
protocol has been approved for the procurement of CB.
CB or peripheral blood (PB) mononuclear cells
(MNCs) were obtained by centrifugation over Ficoll/
Hypaque (Amersham Biosciences, Piscataway, NJ)
gradients. Light density cells were washed twice in
phosphate-buffered saline (PBS; Cambrex, Walkers-
ville, MD) with 1% bovine serum albumin (BSA;
Sigma Chemical Co., St. Louis, MO), and CD341
(positive selection) or CD141 (negative selection) cells
were purified by MidiMACS high-gradient magnetic
separation columns (Miltenyi Biotec, Auburn, CA).
To assess the purity, aliquots of isolated CD341,
CD342, or CD141 cells were restained with anti-
CD34 or anti-CD14 monoclonal antibodies (mAbs)
FITC-conjugated (Becton-Dickinson [BD], San Jose,
CA). PB T cells were immunomagnetically purified
from MNCs on a MidiMACS column by negative se-
lection of non-T cells by using a Pan T Cell Isolation
Kit II (Miltenyi Biotec). This kit utilizes a cocktail of
biotin-conjugated mAbs against CD14, CD16,
CD19, CD36, CD56, CD123, and Glycophorin A as
a primary labeling reagent, and antibiotin mAbs conju-
gated to microbeads as a secondary reagent. The unla-
beled cells that passed through the column were thenstained with an anti-CD3-FITC mAb (BD) as a check
for purity. Isolated CD341, or CD31 T cell samples
were acquired on a FACS Calibur (BD) and analyzed
using the Cell Quest software (BD), and showed, on
average, 95% cell purity. In selected experiments, CB
CD141 monocytes were isolated and then
monocyte-derived immature dendrytic cells (iMo-
DCs) were generated [15]. Briefly, CD141 cells were
cultured in RPMI-10% HS supplemented with 1000
U/mL granulocyte-macrophage colony stimulating
factor (GM-CSF) (Amgen, Thousand Oaks, CA) and
1000 U/mL IL-4 (R&D Systems, Inc., Minneapolis,
MN) for 6 days. Coexpression of HLA-DR, CD86,
and CD1a was analyzed to check the differentiation
of DCs.
Flow Cytometry
Flow cytometric analysis was performed on sam-
ples of PB and CB products. In selected experiments
CB MNCs were stained with mAbs prior to and after
incubation with irradiated (30 Gy) T cells (1:2 ratio)
for 6 days and reisolation over Ficoll/Hypaque. The
following FITC, or PE, or PerCP-conjugated mono-
clonal antibodies (mAbs) were employed: CD34,
HLA-DR, CD14, CD86, CD3, CD11c, and CD19
from Becton-Dickinson, and CD1c (BDCA-1) and
BDCA-2 from Miltenyi Biotec. Appropriate isotype
controls were also utilized.
Primary MLC
Unfractionated CB MNCs, CD341, CD342,
CD3-depleted (TCD), or CD141 cells were freshly
isolated, washed twice, irradiated (30 Gy) and then
tested as stimulators (S) in a primary MLC. Irradiated
CB T cells and autologous PB MNCs were used as
negative controls. Cells were resuspended in medium
containing RPMI-1640 (Cambrex), 10 mM HEPES
(Cambrex), 100 U/mL penicillin (Cambrex), 100 mg/
mL streptomicin (Cambrex), and 10% AB human
serum (HS, HyClone, Logan, UT) inactivated at
56C for 30 min; 5  104 purified PB-derived T cell
responders (R) were mixed with S at 1:2 S/R ratio in
round-bottomed 96-well plates for 6 days at 37C in
a 5% CO2 humidified atmosphere. In selected experi-
ments where CB MNCs were used as S in a primary
MLC, CB MNCs from the same CB were initially
incubated with irradiated (30 Gy) allogeneic T cells.
On day 6 of culture the CB MNCs were harvested,
irradiated, and tested as stimulators in MLC (S:R 5
1:2) with the same responders used in the initial
MLR. Experiments with CB MNCs add-back were
also performed to test if increasing doses of Ag-specific
CB MNCs would suppress the immunostimulatory
activity of CD341 cells. Cells were pulsed with 1
mCi/well 3H-thymidine for 18 hours before harvest
on day 6. Stimulation index (SI) was calculated for
874 S. Chunduri et al.each individual experiment as: SI5 cpm (T cell R1 S)/
cpm (T cell R).
Secondary MLC
After 6-7 days of culture in a primary MLC, T
lymphocytes were harvested, centrifuged over Ficoll/
Hypaque, and rested for 24 to 48 hours at 37C.
Then they were cocultured for 3 days at 1-2  104
cells/well with irradiated CB MNCs (5  104/well),
or CB CD341 cells (2.5  104/well), or Mo-DCs (0.1
 104/well) obtained from the original CB, or for 6
days with third-party PB MNCs (5  104/well).
Cells were pulsed with 1 mCi/well 3H-thymidine
for 18 hours before harvest on day 3 or 6. The SI
was calculated for each individual experiment as: SI
5 cpm (T cell R 1 S)/cpm (T cell R).
CTL Assay
A standard 51Cr release assay was employed as pre-
viously described [16]. Briefly, lymphocytes that had
been primed with irradiated CB MNCs or CB
Mo-DCs for 1 to 4 weeks (effectors) were harvested
and plated, at effector:target (E/T) ratios from 50:1
to 6.25:1, with 1-2  103 51Cr-labeled target cells, in
U-bottomed 96-well plates. After 4 to 6 hours of incu-
bation at 37C, 5% CO2, culture supernatants were
transferred into Luma PlatesTM, which were then
counted on a microplate scintillation counter. PHA-
lymphoblasts, generated by culturing CB MNCs for
6 days in the presence of 10 mg/mL PHA and 20 U/
ml IL-2 were employed as target cells. Target cells
were labeled by an overnight culture at 37C in the
presence of 51Cr at 100 mCi/mL. Results were ex-
pressed as % specific killing, calculated as follows:
(CPM test 2 CPM spontaneous)/(CPM maximum 2
CPM spontaneous)  100, where CPM spontaneous
refers to values detected in wells containing target cells
only, whereas CPM maximum refers to values detected
in wells where target cells were incubated in the
presence of lysing reagents, such as Triton X.
Statistical Analysis
Statistical analysis was performed by using the
t-test (2 tailed), or ANOVA test when more than 2
series of data were compared.
RESULTS
Phenotypic Characterization of Circulating CB
APCs
Circulating APCs include monocytes, myeloid
(mDC), and plasmacytoid (pDC) DC and B cells. To
determine the phenotype of cells used for in vitro ex-
periments, we initially measured the levels of these
cell subsets and CD341 cells, as well as the expression
of HLA-DR and costimulatory molecules such as
CD40, CD80, and CD86, in CB samples prior to(WHOLE CB) and following MNC separation over
Ficoll-Hypaque gradient (MNC CB) (Figure 1).
Results demonstrate that CB grafts contain different
subsets of APCs encompassing CD141 monocytes,
CD191 B cells, and small amounts of CD1c1CD192
mDC and BDCA21 pDC. Flow cytometry analysis
after separation of MNCs revealed an increased
number of monocytes (CD141) (P 5 .01) and expres-
sion of CD80, CD86 (P 5 .01), and CD40 (P 5 .02)
compared to the WHOLE CB, whereas the proportion
of HLA-DR1 cells was not statistically different. The
proportion of CB CD341 or CD141 cells expressing
HLA-DR was on average 51% 6 6% and 35% 6
19%, respectively, and the proportion expressing
CD86 was 1.9%6 0.8% and 82%6 5%, respectively.
Lack of T Cell Alloreactivity to CB MNCs
To test CB MNCs capacity of stimulating T cell
responses in vitro, we initially irradiated CB MNCs
and mixed them with allogeneic T cell responders
(1:1 ratio) in MLC. In addition, irradiated T cell-
depleted (TCD) CB MNCs were also used as stimula-
tors to test the hypothesis of whether by removing CB
T cells we could eliminate a subset of T cells with
suppressive activity. CB T cells and autologous PB
MNCs were utilized after irradiation as negative
controls and third-party PB MNCs as positive control.
CB MNCs did not stimulate any T cell response in
primary MLC independently of the presence or
absence of CB T cells (Figure 2A), suggesting that it
is unlikely that regulatory T cells may inhibit CB
APC activity. On the contrary, when we tested purified
CB CD341 or CD141monocytes as stimulators a clear
T cell response was induced (Figure 2B). To assess if
CB MNCs have a suppressive activity, CB MNCs
and CD341 cells were isolated from the same CB,
and increasing doses of irradiated CB MNCs were
mixed together with a fixed dose of irradiated
CD341 cells (ratio 0.25:1 to 1:1) in primary MLC.
Add-back of CB MNC did not inhibit CD341 cell
immunogenicity (Figure 2C). Similar results were
also obtained mixing CB MNCs with CD141 cells
(data not shown). In addition, supernatants of MLC
with irradiated CB MNCs and allogeneic responders
were tested for the presence of Th1/Th2 type cyto-
kines by means of the Bio-Plex Cytokine immunoassay
(Bio-Rad, Hercules, CA) and no detectable level of any
of the cytokine analyzed was found (not shown). These
findings demonstrate that CB MNCs do not stimulate
allogeneic T cell proliferative responses. However,
they do not have any suppressive function.
CB MNC Do Not Induce T Cell Anergy
We then tested if CB MNCs would induce Ag-spe-
cific T cell unresponsiveness. T cell R that did not pro-
liferate in primary MLC with CB MNCs were
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Figure 1. Flow cytometry analysis of APCs in CB. Phenotypic expression of markers of monocytes (CD14), mDC (CD1c), pDC (BDCA2), HSC
(CD34), B cells (CD19), costimulatory molecules (CD80, CD86, CD40), and HLA-DR was analyzed in unseparated CB cells (WHOLE CB)
(right side) or MNC CB (left side) (n 5 7 experiments). In MNC CB it was observed that a significantly greater percentage of cells expressing
CD80 (P 5 .01), CD86 (P 5 .01), CD14 (P 5 .01), and CD40 (P 5 .02) compared to WHOLE CB, whereas differences for the other markers
were not statistically significant.rechallenged in secondary MLC with irradiation CB
MNCs at 1:2 ratio, or CD341 cells at a 1:1 ratio, or
Mo-DCs at a 10:1 ratio, or third-party PB MNCs at
a 1:2 ratio. Despite the fact that T cells were still unre-
sponsive to CB MNC in secondary MLC, they did
respond to CD341 cells and at a greater extent to Mo-
DCs from the same CB (Figure 3). These results demon-
strate that CB MNCs inefficient APC activity does not
result in antigen-specific T cell anergy. In addition,
these findings point out that, in CB, CD341 cells have
greater APC activity than MNCs, but more limited
than iMo-DCs generated with GM-CSF and IL4.
Stimulation with Allogeneic T Cells Increases CB
MNC Immunogenicity
Freshly isolated CD341 cells can stimulate alloge-
neic T cell responses efficiently [17,18]. In addition,
we have recently demonstrated that CB CD341 cells
can mature into CD11c1CD861 APC upon stimula-
tion with allogeneic T cells that produce cytokinessuch as tumor necrosis factor (TNF)a and GM-CSF
[15], and become more potent APCs within a few
days of culture. Therefore, we tested if allogeneic T
cells can also enhance the APC activity of unselected
CB MNCs. Fresh CB MNC cells did not coexpress
HLA-DR and CD86. Interestingly, coexpression of
HLA-DR and CD86 costimulatory molecule
increased in a small fraction of CB MNC after a
6-day stimulation with T cells (Figure 4A).
More importantly, CB MNCs stimulated by T
cells became also capable of inducing T cell allores-
ponses in MLC (Figure 4B). These results suggest
that a cell:cell contact with allogeneic T cells may rap-
idly increase the allostimulatory effect of CB MNCs.
Delayed Cytotoxic T Lymphocyte (CTL) Activity
Induced by CB MNCs
We next evaluated whether allogeneic PB CTLs
can be generated by stimulation with CB MNCs.
Purified PB T cells were cultured with allogeneic CBCD34+ CD34- CD14 MNC
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Figure 2. Impaired allo-antigen APC activity of CB MNC. (A) CB MNC, or CB T cells (T-ly), or T cell-depleted CB MNC (TCD), or allo-
geneic PB MNC as positive control, were irradiated and mixed with allogeneic T cells in a primary MLC (n 5 5 experiments). PB MNC stim-
ulated a significantly greater T cell response than all the other stimulator cells (P\ .05). (B) Immunomagnetically purified CD341 cells, or
CD342 cells, or CD141 monocytes were compared to MNC from the same CB as stimulators of T cell alloreactivity (n 5 3 experiments)
CD341 and CD141 cells stimulated a significantly greater T cell response than CD342 cells or CB MNCs (P 5 .03). (C) Irradiated CB
MNCs, or CD341 cells, or the combination of CB MNC and CD341 cells at a 1:1 ratio were mixed with allogeneic T cell responders in
MLC (n 5 3 experiments). T cell alloreactivity was measured by 3H-Thymidine incorporation assay after 6 days of culture. Results are shown
as mean SI 6 SD.
876 S. Chunduri et al.MNCs at 2:1 ratio for 1 week, or were restimulated
with CB MNCs weekly for 4 weeks, prior to assessing
their CTL activity against CB PHA blasts at effector:
targets ratios ranging from 6:1 to 50:1, in a standard
51Chromium release assay. CB MNCs failed to elicit
any CTL activity after a standard 7-day priming of al-
logeneic T cell effectors. However, after 4 rounds of
weekly stimulation with CB MNCs, allogeneic CTLs
capable of lysing antigen-specific targets were gener-
ated (Figure 5A). In parallel experiments iMo-DC,
generated by culturing CB CD141 cells with GM-
CSF and IL-4 for 6 days were utilized to stimulate al-
logeneic T cells for 1 week prior to test them in a CTL
assay. In these experiments CB iMo-DC, induced the
generation of CTLs after only 1 week of culture
(Figure 4B). These findings confirm that CB MNC,
are weak APCs but can induce CTL delayed responses
upon repeated stimulation of T cells, comparable to
CTL responses induced by CB iMo-DC, in 1 week.
Simultaneous Induction of CTL Activity by APCs
Derived from 2 CB Grafts
Because allogeneic transplantation of 2 mis-
matched CB units results in long-term engraftment
of only 1 CB unit, we tested whether the separate or
simultaneous stimulation of allogeneic T cells with 2
distinct mismatched CB Mo-DCs would result in
comparable generation of PB CTLs. CD141 cells
were purified from 2 CB units and iMo-DCs were gen-
erated with GM-CSF and IL-4 from each unit (CB1
and CB2) as described in the Materials and Methods
section. Then, iMo-DCs were irradiated and mixed
(1-3  104 cells/well) with allogeneic 5  104 T
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Figure 3. CB MNC do not induce T cell unresponsiveness. Alloge-
neic T cells were stimulated in primary MLC with irradiated CB
MNC for 6 days and were harvested and rested for 1 to 2 days.
Then they were restimulated in a secondary MLC with irradiated
MNC at an S:R ratio of 2:1, or with purified CD341 cells at a 1:1 ra-
tio, or iMo-DC at a 1:10 ratio, all derived from the same CB, for 3
days or with third-party PB MNC for 6 days. Allogeneic T cells
were unresponsive to CB MNC but responded to more potent
APC such as CD341 cells or iMo-DC. Results are shown as mean
S.I. 6 SD of 3 separate experiments.cells/well for 7 days. To test whether CTL activity
was induced by both CB units and if it was Ag-specific
and dose-dependent, irradiated CB1 and CB2 cells
were mixed at 0:1, 1:0, 1:1, 1:2, 1:3, 2:1, and 3:1 ratio
prior to plating them with T cells. In 3 separate exper-
iments, Ag-specific CTL activity was generated with
both CB cells and the CB1:CB2 ratio did not seem
to influence the grade of CTL activity observed. The
percentage of lysis of PHA targets at 50:1 E:T ratio
in 1 representative experiment is shown in Figure 6.
These results suggest that Ag-specific allogeneic
CTL activity can be efficiently induced by 2 distinct
CB-derived APCs simultaneously.
DISCUSSION
In this study we demonstrate that although CB
nucleated cells have a poor alloantigen presenting
activity in vitro, they do not induce T cell unrespon-
siveness and can stimulate delayed T cell alloprolifer-
ative responses after being activated by T cells, or
CTL responses after multiple stimulation of T cell
effectors.
Professional APCs that circulate in CB encompass
monocytes and DCs. Circulating DCs include myeloid
and plasmacytoid subtypes: mDC are identified as
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Figure 4. Increased APC activity of CB MNC after stimulation with
allogeneic T cells. (A) Coexpression of HLA-DR and CD86 costi-
mulatory molecule was tested by flow cytometry in CB MNC cells
freshly isolated (day 0). The same staining was repeated after cultur-
ing CB MNC that had been initially stimulated with irradiated allo-
geneic PB T cells for 6 days and then reseparated over Fycoll/
Hypaque gradients to eliminate the dead T cells (day 6) (see Mate-
rials and Methods). (B) CB MNC freshly isolated or reseparated after
stimulation with T cells (T cell-stimul CB MNC) were irradiated
and mixed with allogeneic PB T cell responders at a 1:1 ratio in
MLC. T cell alloreactivity was measured by 3H-Thymidine incorpo-
ration assay after 6 days of culture. Results are the mean SI6 SD of 3
separate experiments.
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Figure 5. Allogeneic CTL activity induced by multiple restimulations with CB MNC. After priming allogeneic blood T cells with irradiated CB
MNC for 1 or 4 weeks (A), or CB iMo-DC for 1 week (B), the cytotoxic effect against allo-antigen-specific PHA-CB blasts at an effector:target
(E:T) ratio ranging from 6:1 to 50:1 was assessed in a standard 51Cr release assay. CTL generation was observed after stimulation of effectors with
CB MNC for 4 weeks and with CB iMo-DC for 1 week. Autologous control effectors always showed\10% lytic activity. The results are shown as
mean lytic activity 6 SD of 3 separate experiments.HLA-DR1 CD1232CD11c1 and stimulate Th1 re-
sponses, and pDC are identified as HLA-DR1
CD1231CD11c2 and more often induce Th2 re-
sponses [19,20]. Then, mDC can be further dissected
in CD161 and CD162 fractions [21]. In CB, it has
been previously shown that the percentage and abso-
lute number of CD161 and CD162 mDC are smaller
than in PB, whereas CD1231 pDC are increased [22].
Nevertheless, an impaired function of pDC in new-
borns was demonstrated in vitro [23]. Previous exper-
iments on myeloid DCs have shown that after
activation of DCs generated from monocytes (mo-
DC) with LPS, greater amounts of TNFa are pro-
duced by PB than CB DC [8]. Similarly, CB CD141
monocytes, which express less HLA class II molecules
than PB counterparts, show a reduced upregulation of
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Figure 6. Concomitant induction of separate CTL clones induced
by stimulation with APC from double CB units. Allogeneic blood
T cell effectors were mixed with irradiated CB iMo-DC from 2 sep-
arate CB (CB A and B) at different CB:CB ratios ranging from 1:0 to
3:1 (CB:T cell ratio from 1:1 to 3:1) for 7 days. Then cytotoxic activ-
ity of effector cells against PHA blasts obtained from each CB (target
A and target B) was measured in a standard 51Cr release assay at
a 50:1 E:T ratio. This result is representative of 3 separate experi-
ments.HLA-DR and CD40 compared to PB monocytes upon
stimulation with LPS [8] or Interferon g (IFNg) [24].
Because the number of mDCs is reduced in maternal
blood [25] at the time of delivery, it has been specu-
lated that the APC activity of both CB and mother
PB DCs is impaired to facilitate immune tolerance
during pregnancy.
In this study, we analyzed whether CB nucleated
cells that are commonly utilized in HSC transplanta-
tion may stimulate T cells responses or favor alloge-
neic T cell unresponsiveness. Because our initial
findings showed that CB MNCs do not stimulate any
allogeneic T cell response in vitro, we utilized T
cell-depleted MNCs to test whether the suppressive
activity could be because of T cell suppressors or reg-
ulatory T cells present in the CB graft. To this purpose
we utilized 2 separate methods of T cell depletion. Im-
munomagnetic negative selection of CD31 cells re-
sulted in a CD3 negative cell population that showed
no allostimulatory effect, comparable to the whole
CB MNCs. This finding ruled out the effect of CB reg-
ulatory T cells suppressing alloreactivity, and also the
hypothesis that CB MNCs may be not allostimulatory
because of a greater content of resting/naı¨ve T cells
compared to PB MNCs. In contrast, after T cell deple-
tion by selecting CD341 cells we obtained a cell
population with increased APC activity. The allosti-
mulatory effect was similar to what previously ob-
served using marrow or blood CD341 cells [17,18].
Therefore, we hypothesize that in case T cell depletion
is pursued in CB transplant, different methods may af-
fect the immunogenic properties of the graft substan-
tially. The different allostimulatory effect of CD341
cells and MNC within the same CB allowed us to per-
form add-back experiments that showed that CD341
cells maintained their immunogenic effect despite
the presence of MNC at a 1:1 ratio, and therefore ruled
out an inhibitory effect of CB MNCs. The next ques-
tion was whether the inability of CB MNC to deliver
878 S. Chunduri et al.adequate signaling to allogeneic T cells would result in
T cell anergy. Rechallenge of T cells with CB MNCs
indeed resulted in unresponsiveness. However, rechal-
lenge of T cells initially stimulated by CB MNCs with
CD341 cells or iMo-DC carrying the same alloantigen
obtained potent secondary proliferative responses, rul-
ing out the capacity of CB MNC to induce T cell
anergy. A possible explanation for the inability of CB
MNCs to trigger T cell responses may be because of
the low expression of HLA-DR in CB MNCs, as op-
posed to CD341 cells, that prevents enough signaling
to T cell receptor on T cells. Interestingly, after cocul-
ture of CB MNCs with irradiated allogeneic T cells for
6 days, an increase of cells coexpressing HLA-DR and
CD86 was detected and CB MNCs that had been stim-
ulated with T cells could then become capable of in-
ducing allogeneic T cell responses in vitro. It is
conceivable that this subset of CB MNCs upregulating
the CD86 costimulatory molecule includes also
CD341 cells, which can be rapidly induced to upregu-
late costimulatory molecules [26] and differentiate into
APC upon contact with alloreactive T cells [15]. As ex-
pected, the weak APC activity of CB MNCs did not
elicit allogeneic CTL responses in a standard 1-week
assay. Nevertheless, 4 weekly restimulations of alloge-
neic T cells with CB MNCs resulted in the generation
of CTLs capable of lysing CB targets. Altogether,
these results may suggest that CB MNCs are unable
to induce an immediate T cell alloreactivity. However,
activation/differentiation of APC in the graft upon
contact with T cells, and prolonged stimulation of al-
logeneic effectors by CB cells will result in both prolif-
erative and cytotoxic responses.
These in vitro results allow us to speculate on pos-
sible in vivo effects. In fact, the scarce initial immuno-
genic function of CB APCs may prevent the initial
rejection of the graft in recipients of HLA mismatch
grafts and may contribute to reducing the develop-
ment of aGVHD by the lack of indirect antigen pre-
sentation. Nevertheless, our findings suggest that CB
MNCs include cells that can stimulate delayed allo-
reactivity. This could result in delayed graft rejection
or failure of engraftment because of residual host T
cells. In alternative, a delayed activation of CB-derived
APCs could also contribute to the development of
cGVHD by means of indirect presentation of alloanti-
gens [14].
We also show here that CTL responses obtained
after 4 weeks of restimulation of T cell effectors with
CB MNCs were similar to what observed in 1 week
with CB iMo-DCs. Then, in our experiments stimu-
lating T cells with CB iMo-DCs from 2 CB units con-
comitantly, we could generate antigen-specific CTLs
against each CB unit independently of the CB:CB ra-
tio. We expect that a few weeks after transplant CB
MNCs will be able to activate alloresponses of T cells
of the host, and/or of the second CB unit in case ofdouble transplant. In vivo experiments in nonobese
diabetic(NOD)/SCID/gcnull mice have previously
shown that both CB CD41 and CD81 cells are neces-
sary to reproduce the skewed chimerism observed in
human recipients [27]. Despite the mechanism(s) for
the competitive long-term engraftment of only 1 CB
unit observed in recipients of double CB transplant
still remains unclear, our data may suggest that
changes in the phenotype and function of CB cell sub-
sets after transplants should be further investigated as
possible mediators of selective T cell alloreactivity or
in vivo peripheral tolerance.
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